Literature DB >> 26325587

Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis.

Noriko Masubuchi1, Masahiro Sugihara2, Tomonori Sugita3, Katsushi Amano3, Masanori Nakano3, Tomokazu Matsuura4.   

Abstract

Clinicians sometimes encounter difficulty in choosing a therapeutic strategy due to the uncertainty regarding the type of liver injury. In particular, cholestasis is difficult to diagnose by conventional markers at an early stage of disease. The aim of this study was to identify promising biomarkers for distinguishing the symptom-based types of liver injury (e.g. hepatocellular injury, cholestasis), which was derived from a rigorously statistical perspective. The associations between diagnostic biomarkers (e.g. bile acid components, oxidative stress markers and liver fibrosis markers) and the liver injury types were assessed by a multiple logistic regression analysis using 304 blood samples from patients with liver disease. As a result, reductions in the lithocholic acid (LCA) and deoxycholic acid (DCA) levels, and elevation of the serum sulfated bile acid (SSBA), liver fibrosis marker IV collagen (type IV collagen), hyaluronic acid (HA) and reactive oxygen species (ROS) levels were all significantly associated with cholestasis. On the other hand, elevations in the LCA and type IV collagen levels, and a reduction in the ursodeoxy cholic acid (UDCA) level, were significantly associated with hepatocellular injury. The receiver operating characteristic (ROC) analyses showed that the largest area under the ROC curve (AUC) was found for ROS, followed by DCA, HA, LCA, SSBA and type IV collagen in the cholestatic-type cases. These results indicated that ROS, the secondary bile acid levels such as DCA and LCA, and SSBA are promising biomarkers for cholestasis and for classifying the type of liver injuries. This comprehensive approach will allow for an accurate diagnosis, which will facilitate the selection of an appropriate therapy at the onset of disease.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cholestasis; Deoxycholic acid; Hepatocellular injury; Lithocholic acid; Oxidative stress

Mesh:

Substances:

Year:  2015        PMID: 26325587     DOI: 10.1016/j.cbi.2015.08.016

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  10 in total

1.  Loss of c-Met signaling sensitizes hepatocytes to lipotoxicity and induces cholestatic liver damage by aggravating oxidative stress.

Authors:  Luis E Gomez-Quiroz; Daekwan Seo; Yun-Han Lee; Mitsuteru Kitade; Timo Gaiser; Matthew Gillen; Seung-Bum Lee; Ma Concepcion Gutierrez-Ruiz; Elizabeth A Conner; Valentina M Factor; Snorri S Thorgeirsson; Jens U Marquardt
Journal:  Toxicology       Date:  2016-07-06       Impact factor: 4.221

Review 2.  Regulation of bile acid metabolism-related signaling pathways by gut microbiota in diseases.

Authors:  Er-Teng Jia; Zhi-Yu Liu; Min Pan; Jia-Feng Lu; Qin-Yu Ge
Journal:  J Zhejiang Univ Sci B       Date:  2019 Oct.       Impact factor: 3.066

Review 3.  Challenges and Future of Drug-Induced Liver Injury Research-Laboratory Tests.

Authors:  Sabine Weber; Alexander L Gerbes
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

4.  Novel in Vitro Method Reveals Drugs That Inhibit Organic Solute Transporter Alpha/Beta (OSTα/β).

Authors:  Melina M Malinen; Antti Kauttonen; James J Beaudoin; Noora Sjöstedt; Paavo Honkakoski; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2018-12-14       Impact factor: 4.939

5.  Metabolomic profile overlap in prototypical autoimmune humoral disease: a comparison of myasthenia gravis and rheumatoid arthritis.

Authors:  Derrick Blackmore; Liang Li; Nan Wang; Walter Maksymowych; Elaine Yacyshyn; Zaeem A Siddiqi
Journal:  Metabolomics       Date:  2020-01-04       Impact factor: 4.290

6.  Gasdermin E-derived caspase-3 inhibitors effectively protect mice from acute hepatic failure.

Authors:  Wan-Feng Xu; Quan Zhang; Chu-Jie Ding; Hui-Yong Sun; Yuan Che; Hai Huang; Yun Wang; Jia-Wei Wu; Hai-Ping Hao; Li-Juan Cao
Journal:  Acta Pharmacol Sin       Date:  2020-05-26       Impact factor: 6.150

7.  Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans.

Authors:  Lina Luo; Jiri Aubrecht; Dingzhou Li; Roscoe L Warner; Kent J Johnson; Julia Kenny; Jennifer L Colangelo
Journal:  PLoS One       Date:  2018-03-07       Impact factor: 3.240

8.  Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats via CAR activation.

Authors:  Daniela Gabbia; Luisa Pozzo; Giorgia Zigiotto; Marco Roverso; Diana Sacchi; Arianna Dalla Pozza; Maria Carrara; Sara Bogialli; Annarosa Floreani; Maria Guido; Sara De Martin
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

9.  Targeted Metabolomics With Ultraperformance Liquid Chromatography-Mass Spectrometry (UPLC-MS) Highlights Metabolic Differences in Healthy and Atopic Staffordshire Bull Terriers Fed Two Different Diets, A Pilot Study.

Authors:  Robin Moore; Johanna Anturaniemi; Vidya Velagapudi; Jatin Nandania; Stella Maria Barrouin-Melo; Anna Hielm-Björkman
Journal:  Front Vet Sci       Date:  2020-10-27

10.  Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.

Authors:  Kiran V K Koelfat; Denis Picot; Xinwei Chang; Ronan Thibault; Frank G Schaap; Steven W M Olde Damink; Mireille Desille-Dugast; Hans M van Eijk; Sander M J van Kuijk; Martin Lenicek; Sabrina Layec; Marie Carsin; Laurence Dussaulx; Eloi Seynhaeve; Florence Trivin; Laurence Lacaze
Journal:  Hepatology       Date:  2021-08-26       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.